BVMed clears a way through the German pre-market maze
This article was originally published in Clinica
Executive Summary
German device companies attempting to steer through the Euro62bn ($78bn) German hospital treatments sector will need a good wayfinder. Regulatory approval and reimbursement have recently been joined by more potential obstacles in DRGs and HTA. A good job, then, that BVMed industry association head Joachim Schmitt seems to know the route